Hong Kong
· Delayed Price · Currency is HKD BeiGene Company Description
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
| Country | Cayman Islands |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | John Oyler |
Contact Details
Address: 94 Solaris Avenue Camana Bay, KY1-1108 Cayman Islands | |
| Phone | 345-949-4123 |
| Website | beigene.com |
Stock Details
| Ticker Symbol | 6160 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG1146Y1017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John V. Oyler | Co-Founder, Executive Chairman and Chief Executive Officer |
| Dr. Xiaobin Wu Ph.D. | President and Chief Operating Officer |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board and Non-Executive Director and Co-Founder |
| Chan Lee | General Counsel and Senior Vice President |
| Wang Lai Ph.D. | Global Head of Research & Development |
| Aaron Rosenberg | Chief Financial Officer and Principal Financial Officer |
| Titus B. Ball | Vice President and Chief Accounting Officer |
| Liza Heapes | Head of Investor Relations |
| Yang Ji | Chief Compliance Officer |
| Dr. Yan Qi | Senior Vice President and Head of Public Affairs - Greater China |